Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q1 FY26 results · Apr–Jun 2025
Neuland Laboratories reported revenue from operations of ₹292.75 crore (down 33.4% from Q1 FY25) and net profit of ₹13.90 crore (down 85.8% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 292.75 | 439.60 | −33.4% | 328.36 | −10.8% |
| Other income | 7.86 | 4.81 | +63.4% | 7.46 | +5.2% |
| Total income | 300.61 | 444.41 | −32.4% | 335.82 | −10.5% |
| Profit before tax | 17.57 | 129.84 | −86.5% | 39.30 | −55.3% |
| Net profit for the period | 13.90 | 97.87 | −85.8% | 27.81 | −50.0% |
| EPS, basic (₹) | 10.83 | 76.28 | −85.8% | 21.67 | −50.0% |
| Net margin (%) | 4.7 | 22.3 | 8.5 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 292.75 | 439.60 | −33.4% | 328.36 | −10.8% |
| Other income | 7.86 | 4.81 | +63.4% | 7.46 | +5.3% |
| Total income | 300.61 | 444.41 | −32.4% | 335.82 | −10.5% |
| Profit before tax | 17.38 | 130.31 | −86.7% | 38.98 | −55.4% |
| Net profit for the period | 13.71 | 98.34 | −86.1% | 27.73 | −50.6% |
| EPS, basic (₹) | 10.68 | 76.65 | −86.1% | 21.62 | −50.6% |
| Net margin (%) | 4.7 | 22.4 | 8.4 |
Consolidated
- Filed with BSE
- 31 Jul 2025, 17:08 IST
- Board meeting
- 31 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Jul 2025, 17:08 IST
- Board meeting
- 31 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE